Paper33014387
Introduction to immunotherapy for brain tumor patients: challenges and future perspectives.
Montoya ML and 2 others. Neurooncol Pract, 2020. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. Papers, record 33014387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33014387
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Introduction to immunotherapy for brain tumor patients: challenges and future perspectives.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA222965 | NCI NIH HHS | United States | R01CA222965 | PubMed | NIH RePORTER |
| R21 NS104454 | NINDS NIH HHS | United States | R21NS104454 | PubMed | NIH RePORTER |
| R35 NS105068 | NINDS NIH HHS | United States | R35NS105068 | PubMed | NIH RePORTER |
References95
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29244745 | Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity. | Viruses | 2017 | https://conductscience.org/library/papers/29244745 | PubMed |
| 2 | 31320597 | A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31320597 | PubMed |
| 3 | 22661320 | K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. | Acta Neuropathol | 2012 | https://conductscience.org/library/papers/22661320 | PubMed |
| 4 | 31040917 | PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. | Oncotarget | 2019 | https://conductscience.org/library/papers/31040917 | PubMed |
| 5 | 28426845 | HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. | JAMA Oncol | 2017 | https://conductscience.org/library/papers/28426845 | PubMed |
| 6 | 27314913 | Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. | Hum Gene Ther Clin Dev | 2016 | https://conductscience.org/library/papers/27314913 | PubMed |
| 7 | 23462419 | Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. | Int J Radiat Oncol Biol Phys | 2013 | https://conductscience.org/library/papers/23462419 | PubMed |
| 8 | 26545842 | Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26545842 | PubMed |
| 9 | 20727764 | CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. | J Clin Neurosci | 2010 | https://conductscience.org/library/papers/20727764 | PubMed |
| 10 | 24764576 | Oncolytic viruses and their application to cancer immunotherapy. | Cancer Immunol Res | 2014 | https://conductscience.org/library/papers/24764576 | PubMed |
| 11 | 27020328 | Corticosteroids compromise survival in glioblastoma. | Brain | 2016 | https://conductscience.org/library/papers/27020328 | PubMed |
| 12 | 19116635 | Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. | Mol Ther | 2009 | https://conductscience.org/library/papers/19116635 | PubMed |
| 13 | 24553386 | Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. | Sci Transl Med | 2014 | https://conductscience.org/library/papers/24553386 | PubMed |
| 14 | 28029927 | Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. | N Engl J Med | 2016 | https://conductscience.org/library/papers/28029927 | PubMed |
| 15 | 25517610 | Balance and imbalance in the immune system: life on the edge. | Immunity | 2014 | https://conductscience.org/library/papers/25517610 | PubMed |
| 16 | 31646087 | Trial watch: dendritic cell vaccination for cancer immunotherapy. | Oncoimmunology | 2019 | https://conductscience.org/library/papers/31646087 | PubMed |
| 17 | 27120786 | IDH-1R132H mutation status in diffuse glioma patients: implications for classification. | Oncotarget | 2016 | https://conductscience.org/library/papers/27120786 | PubMed |
| 18 | 30568305 | Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. | Nature | 2019 | https://conductscience.org/library/papers/30568305 | PubMed |
| 19 | 24329793 | Design and development of therapies using chimeric antigen receptor-expressing T cells. | Immunol Rev | 2014 | https://conductscience.org/library/papers/24329793 | PubMed |
| 20 | 29087782 | Vaccination in the immunotherapy of glioblastoma. | Hum Vaccin Immunother | 2018 | https://conductscience.org/library/papers/29087782 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42156731 | Non-lytic viral immunotherapy induces long-term glioblastoma survival and tumor-specific immunity without eliciting an antiviral response. | Nat Commun | 2026 | https://conductscience.org/library/papers/42156731 | PubMed |
| 41993610 | Translational Models for Glioblastoma: Revolutionizing Drug Development and Personalized Medicine through Clinical Insights. | Theranostics | 2026 | https://conductscience.org/library/papers/41993610 | PubMed |
| 41166287 | Identification of natural Zika virus peptides presented on the surface of paediatric brain tumour cells by HLA class I. | PLoS One | 2025 | https://conductscience.org/library/papers/41166287 | PubMed |
| 40507329 | Immunotherapy for High-Grade Gliomas. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40507329 | PubMed |
| 40047938 | Prostaglandin F2 receptor negative regulator as a potential target for chimeric antigen receptor-T cell therapy for glioblastoma. | Cancer Immunol Immunother | 2025 | https://conductscience.org/library/papers/40047938 | PubMed |
| 39799339 | Personalising glioblastoma medicine: explant organoid applications, challenges and future perspectives. | Acta Neuropathol Commun | 2025 | https://conductscience.org/library/papers/39799339 | PubMed |
| 39669560 | A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence. | Front Immunol | 2024 | https://conductscience.org/library/papers/39669560 | PubMed |
| 37129737 | Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model. | J Neurooncol | 2023 | https://conductscience.org/library/papers/37129737 | PubMed |
| 36601313 | Identification of glioblastoma-specific antigens expressed in patient-derived tumor cells as candidate targets for chimeric antigen receptor T cell therapy. | Neurooncol Adv | 2023 | https://conductscience.org/library/papers/36601313 | PubMed |
| 35990704 | The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review. | Neurooncol Adv | 2022 | https://conductscience.org/library/papers/35990704 | PubMed |
| 34765977 | A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma. | Neurooncol Adv | 2021 | https://conductscience.org/library/papers/34765977 | PubMed |
| 34539626 | Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades. | Front Immunol | 2021 | https://conductscience.org/library/papers/34539626 | PubMed |
| 34466804 | Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. | Neurooncol Adv | 2021 | https://conductscience.org/library/papers/34466804 | PubMed |
| 34321465 | MicroRNA-361-5p slows down gliomas development through regulating UBR5 to elevate ATMIN protein expression. | Cell Death Dis | 2021 | https://conductscience.org/library/papers/34321465 | PubMed |
| 34041027 | World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology. | Front Oncol | 2021 | https://conductscience.org/library/papers/34041027 | PubMed |
| 33918043 | Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33918043 | PubMed |
| 33524947 | Using viral vectors to deliver local immunotherapy to glioblastoma. | Neurosurg Focus | 2021 | https://conductscience.org/library/papers/33524947 | PubMed |
| 33389564 | Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies. | J Neurooncol | 2021 | https://conductscience.org/library/papers/33389564 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33014387
GET https://conductscience.org/api/papers/v1/33014387/references?page=2